Triochem Products
17.40
0.00(0.00%)
Market Cap₹0.40 Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D0.00%
1M0.00%
6M0.00%
1Y0.00%
5Y0.00%
View Company Insightsright
More news about Triochem Products
13Dec 25
Triochem Products Completes ₹11.81 Crore Asset Sale Approval via Postal Ballot
Triochem Products has successfully concluded its postal ballot process with unanimous shareholder approval for the ₹11.81 crore asset sale in Maharashtra. The transaction, approved with 14,000 votes in favor and zero against, involves property disposal at significant premium over written down value, providing crucial funds to address the company's recent operational losses and support future strategic initiatives in the chemicals and pharmaceuticals sector.
 no imag found
04Nov 25
Triochem Products Limited Seeks Shareholder Approval for Rs 11.81 Crore Asset Sale to Related Parties
Triochem Products Limited has announced plans to sell non-core assets valued at Rs 11.81 crore to related parties. The assets include residential flats, an industrial plot with factory buildings, and plant and machinery. The buyers are M/s G Amphray Laboratories and Mr. Rajesh Ramu Deora, who are related parties. The company is seeking shareholder approval through a postal ballot, with voting open from November 13 to December 12. The sale is based on independent valuations and complies with regulatory requirements. The company states that the sale will not adversely impact its operations.
 no imag found
24Oct 25
Triochem Products Board Approves Sale of Non-Core Assets Worth Rs 11.81 Crore
Triochem Products Limited has approved the sale of non-core assets valued at Rs 11.81 crore. The sale includes properties and plant & machinery to G Amphray Laboratories for Rs 8.06 crore and a residential flat to director Rajesh Ramu Deora for Rs 3.75 crore. These assets contributed 0% to the company's turnover last year. The sale, subject to shareholder approval, is expected to complete by January 31, 2026. Proceeds will be used for new business ventures and strategic initiatives. The company has also approved amendments to Related Party Transaction policies and a postal ballot process.
 no imag found
18Aug 25
Triochem Products Reports Widened Q1 Net Loss of Rs. 15.24 Crore
Triochem Products Limited reported a net loss of Rs. 15.24 crore for Q1, a 58.42% increase from the previous year's Q1 loss of Rs. 9.62 crore. Total income remained relatively stable at Rs. 22.10 crore, down 3.79% year-on-year. Despite the net loss, the company reported a total comprehensive income of Rs. 89.27 crore. The Q1 EPS was negative Rs. 1.25, an improvement from the previous quarter's negative Rs. 18.44. The Board approved these unaudited financial results on August 14, prepared in accordance with Indian Accounting Standards.
 no imag found
Triochem Products
17.40
0.0
(0.0%)
1 Year Returns:0.00%
Industry Peers
Sun Pharmaceutical
1,801.60
(-1.30%)
Divis Laboratories
6,071.00
(-3.36%)
Torrent Pharmaceuticals
4,390.00
(-1.26%)
Dr Reddys Laboratories
1,292.30
(-2.02%)
Cipla
1,314.70
(-0.72%)
Lupin
2,314.90
(-1.80%)
Zydus Life Science
905.90
(-1.20%)
Mankind Pharma
2,138.90
(-3.13%)
Aurobindo Pharma
1,296.50
(-1.17%)
Alkem Laboratories
5,355.50
(-1.63%)